Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debora Fumagalli

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Current Opinion in Oncology|September 28, 2011
Unravelling the epigenomic dimension of breast cancersSarah Dedeurwaerder, Debora Fumagalli, François Fuks
Current Opinion in Oncology|September 11, 2012
Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?Dimitrios Zardavas, Debora Fumagalli, Sherene Loi
Cancers|April 30, 2021
Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?Cinzia Solinas, Debora Fumagalli, Maria Vittoria Dieci
Cancer Treatment Reviews|August 25, 2014
Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?Amir Sonnenblick, Debora Fumagalli, Christos Sotiriou, et al.
Oncotargets and Therapy|May 10, 2011
Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selectionCarmen Criscitiello, Debora Fumagalli, Kamal S Saini, et al.
Science Translational Medicine|September 3, 2010
Molecular profiling: moving away from tumor philatelyJorge S Reis-Filho, Britta Weigelt, Debora Fumagalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2014
New strategies in breast cancer: the significance of molecular subtypes in systemic adjuvant treatment for small T1a,bN0M0 tumorsAmir Sonnenblick, Debora Fumagalli, Hatem A Azim, et al.
Critical Reviews in Oncology/Hematology|September 12, 2012
Molecular biology in breast cancer: should molecular classifiers be assessed by conventional tools or by gene expression arrays?Debora Fumagalli, Fabrice Andre, Martine J Piccart-Gebhart, et al.
Journal of the National Cancer Institute. Monographs|November 2, 2011
Gene profiling assay and application: the predictive role in primary therapyDebora Fumagalli, Christine Desmedt, Michail Ignatiadis, et al.
Therapeutic Advances in Medical Oncology|March 6, 2019
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectivesRafael Caparica, Matteo Lambertini, Noam Pondé, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Current Opinion in Oncology|September 28, 2011
Unravelling the epigenomic dimension of breast cancersSarah Dedeurwaerder, Debora Fumagalli, François Fuks
Current Opinion in Oncology|September 11, 2012
Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?Dimitrios Zardavas, Debora Fumagalli, Sherene Loi
Cancers|April 30, 2021
Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?Cinzia Solinas, Debora Fumagalli, Maria Vittoria Dieci
Cancer Treatment Reviews|August 25, 2014
Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?Amir Sonnenblick, Debora Fumagalli, Christos Sotiriou, et al.
Oncotargets and Therapy|May 10, 2011
Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selectionCarmen Criscitiello, Debora Fumagalli, Kamal S Saini, et al.
Science Translational Medicine|September 3, 2010
Molecular profiling: moving away from tumor philatelyJorge S Reis-Filho, Britta Weigelt, Debora Fumagalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2014
New strategies in breast cancer: the significance of molecular subtypes in systemic adjuvant treatment for small T1a,bN0M0 tumorsAmir Sonnenblick, Debora Fumagalli, Hatem A Azim, et al.
Critical Reviews in Oncology/Hematology|September 12, 2012
Molecular biology in breast cancer: should molecular classifiers be assessed by conventional tools or by gene expression arrays?Debora Fumagalli, Fabrice Andre, Martine J Piccart-Gebhart, et al.
Journal of the National Cancer Institute. Monographs|November 2, 2011
Gene profiling assay and application: the predictive role in primary therapyDebora Fumagalli, Christine Desmedt, Michail Ignatiadis, et al.
Therapeutic Advances in Medical Oncology|March 6, 2019
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectivesRafael Caparica, Matteo Lambertini, Noam Pondé, et al.
Pageof 7